Avinger Inc

Avinger — IPO Roadshow (February 2018)

46 slides from Avinger's IPO roadshow presentation, Feb 5, 2018

  1. Slide 1: Lumivascular Image Guided Therapy

    LUMIVASCULAR IMAGE GUIDED THERAPY AVINGER

  2. Slide 2: Safe Harbor

    Safe Harbor AVINGER OVERVIEW 2017 PAGE 2 These slides and the accompanying oral presentation contain forward-looking statements about Avinger, Inc. (“Avinger” or the “Company”) and its business. All statements other than statements of historical fact contained in this presentation, including stateme

  3. Slide 3: Free Writing Prospectus

    FREE WRITING PROSPECTUS AVINGER OVERVIEW 2017 PAGE 3 This presentation highlights basic information about us and the offering. Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in our

  4. Slide 4: Unique and Differentiated Approach

    4 UNIQUE AND DIFFERENTIATED APPROACH Lumivascular Platform is the only technology that combines real-time intravascular imaging with highly effective therapy for treatment of Peripheral Artery Disease (PAD) Over 21 million people projected to suffer from PAD in United States alone by 20201 COMPANY O

  5. Slide 5: Lumivascular: Combining Real-Time Intravascular Imaging with Therapeutic Devices

    LUMIVASCULAR adjestive : COMBINING REAL-TIME INTRAVASCULAR IMAGING WITH THERAPEUTIC DEVICES TO AVOID DAMAGING THE NATIVE ARTERY.

  6. Slide 6: Lumivascular Approach: OCT Image-Guided Therapy vs Fluoroscopy

    6 lumivascular approach OCT Image-guided therapy Fluoroscopy (X-Ray)

  7. Slide 7: Arterial Damage Leads to Restenosis

    Arterial Damage Leads to restenosis The external elastic lamina defines the border within the layers of the artery. Disrupting the external elastic lamina leads to accelerated restenosis. 7

  8. Slide 8: Minimizing Damage to Adventitia

    Minimizing damage to adventitia lumivascular Histopathological Evidence of Adventitial or Medial Injury is a Strong Predictor of Restenosis During Directional Atherectomy for Peripheral Artery Disease. J Endovasc Ther. 2015 Oct;22l5l:712-5. doi: 10.1177/1526602815597683. Epub 2015 Jul 24 FIH Data on

  9. Slide 9: Lumivascular Platform

    lumivascular platform only technology that offers real-time visualization of the inside of the artery during Peripheral Artery Disease (PAD) treatment 9 152 installed units FDA 510(k) cleared CE Mark Imaging console “RAZOR” Image-guided Atherectomy catheter Improved version (3.0) pending FDA 510(k)

  10. Slide 10: Pipeline and Upcoming Milestones

    Product Market Opportunity Expected FDA Clearance / Product Launch Commentary Pantheris 3.0 $280M ATK H1 2018 Next generation image guided atherectomy Pantheris 6F (BTK) “Below the Knee” $180M BTK H2 2018 Longer length, lower profile for BTK (below-the-knee) Ocelaris PAD $90M H1 2019 Next generation

  11. Slide 11: Pantheris Lumivascular Atherectomy

    PANTHERIS LUMIVASCULAR ATHERECTOMY

  12. Slide 12: Lumivascular AT

    LUMIVASCULAR AT

  13. Slide 13: Pantheris: Visualization. Precision. Safety.

    13 Pantheris Visualization. Precision. Safety. EEL Adventitia Media Balloon Middle Marker Balloon Disease Balloon EEL Media VISUALIZE the disease Cut with PRECISION Stay SAFE and don’t perforate

  14. Slide 14: Competitive Positioning

    Competitive positioning COMPANY PRODUCT MARKET SHARE APPROACH LUMINAL GAIN AVOIDS ADVENTITIA DISRUPTION REMOVAL OF PLAQUE RADIATION & CONTRAST SPARING IMAGING & VESSEL MEASUREMENT Avinger Pantheris <5% Directional Atherectomy Covidien / Medtronic SilverHawk 29% Directional Atherectomy CSI Diamondbac

  15. Slide 15: Pantheris 3.0 – FDA 510(k) Submitted Q4 2017

    Pantheris 3.0 – FDA 510(k) Submitted q4 2017 Product Specifications Currently in development at Avinger. Not available for sale 15 Petal Cutter Provides increased cutting efficiency and enhanced tissue engagement Redesigned Inflation System Single balloon for apposition and blood flow management Lon

  16. Slide 16: Pantheris 6F (BTK) – FDA 510(k) Submission Planned

    Pantheris 6F (BTK) – fda 510(K) SUBMISSION PLANNED Product Specifications Currently in development at Avinger. Not available for sale 16 Slimmer profile 140cm working length 1:1 torque transmission “Cobra” jog for apposition of cutter to tissue 3.5cm nosecone ENHANCEMENTS BENEFITS Compatible with 6F

  17. Slide 17: Ocelot Lumivascular CTO Crossing

    OCELOT LUMIVASCULAR CTO CROSSING

  18. Slide 18: Ocelot Lumivascular CTO Crossing

    18 ocelot Lumivascular Cto Crossing Bullet 1 Bullet 2 Bullet 3 Bullet 4 Bullet 5

  19. Slide 19: Ocelaris: Next Generation CTO Crossing

    Ocelaris: Next generation cto crossing 1000 RPM rotation speed generates Pantheris-like imaging and enhanced CTO crossability Low profile design allows for 5F sheath compatibility Variable angle tip deflection delivers precise maneuverability Anticipated Peripheral version H1 2019 Anticipated Corona

  20. Slide 20: Commercial Drivers

    commercial drivers Next Generation Products Pantheris 3.0 Ocelaris CTO Crosser (PAD) Lightbox L300 Platform New Product Initiatives Below-the-Knee Pantheris Atherectomy Catheter Ocelaris Coronary CTO Crosser Diagnostic Imaging Catheter for Peripheral and Coronary Coronary Atherectomy OCT Diagnostic

  21. Slide 21: Lightbox L300 Platform

    21 Lightbox L300 Platform Radically reduced footprint for easier lab integration Multiple system installation options Lab integrated option Cart-based option Variable speed catheter rotation (1,000 – 10,000 RPM) delivering enhanced OCT imaging and optimal device effectiveness Sterile field control s

  22. Slide 22: OCT Diagnostic Reimbursement

    Proposed Rule: new diagnostic imaging code/reimbursement for OCT in peripheral arteries (PAD) Incremental to already strong atherectomy procedural reimbursement Similar to existing intravascular ultrasound (IVUS) reimbursement Would apply to Ocelot, Pantheris and future OTC image-guided products Str

  23. Slide 23: Clinical Data and Regulatory Programs

    Label Expansion for In-Stent Restenosis (ISR) Lesions CE-Mark approval for ISR claim Sept 2017 FDA approval of IDE application for INSIGHT study April 2017 20 US/OUS Sites // up to 140 subjects 30-day follow-up for labeling safety claim; Follow-up will continue at 6 and 12 months Enrollment initiate

  24. Slide 24: U.S. and International Sales Regions

    U.S. and international sales regions 24 National Agreements Europe/Middle East Direct sales in Germany (1 Sales Director); sales through distributors in Switzerland, UAE and Turkey Japan Manufacturing facility registration with PMDA, Jan 2017 US Europe Japan China Regulatory Approval Process Initiat

  25. Slide 25: Attractive and Growing Market

    ATTRACTIVE and growing MARKET ($ in billions) U.S. PV Device Market is expected to be $3.6 billion in 2018 and expected to grow at a rate of 2.3% until 2023 U.S. PV DEVICE MARKET Treatment Procedures Market Size Amputations(1) 200,000 - Bypass(2) 160,000 - Surgical Procedures 360,000 - Stents(3) 314

  26. Slide 26: Key 2018 Milestones

    KEY 2018 milestones 26 Expected FDA clearance of Pantheris 3.0 – H1 2018 Anticipated filing of 510(k) for Pantheris BTK – mid-2018, with expected FDA clearance in H2 2018 Anticipated filing of CPT application for OCT diagnostic reimbursement – Q2 2018 Target completion of enrollment in ISR clinical

  27. Slide 27: Key 2018 Milestones

    KEY 2018 MILESTONES Expected FDA clearance of Pantheris 3.0 — H1 2018 Anticipated filing of 510(k) for Pantheris BTK — mid-2018, with expected FDA clearance in H2 2018 Anticipated filing of CPT application for OCT diagnostic reimbursement — Q2 2018 Target completion of enrollment in ISR clinical stu

  28. Slide 28: CRG Partners Debt

    28 CRG PARTNERS DEBT Balance As of December 31, 2017: $44.5 million CRG Partners has agreed to convert a significant portion of its secured debt into newly authorized non-voting convertible preferred stock. Conversion rate based on pricing of equity financing 19.99% cap and subject to shareholder vo

  29. Slide 29: Financials

    FINANCIALS 29 As of December 31, 2017 ($ in millions) LTM Revenue $9.9 Cash and Equivalents $5.4 * Cash Burn equals Net Change in Cash less Cash Flows from Financing $4.4 $3.0 $2.3 $1.6 1Q17A 2Q17A 3Q17A 4Q17A Avg Monthly Cash Burn * ($M)

  30. Slide 30: Appendix

    AVINGER OVERVIEW 2016 PAGE 30 PRESENTATION TITLE presentation Subtitle Bullet 1 Bullet 2 Bullet 3 Bullet 4 Bullet 5 APPENDIX

  31. Slide 31: Management Team – Jeff Soinski

    31 Management team Jeff Soinski – Chief Executive Officer Jeff Soinski has served as our President, Chief Executive Officer and a member of our Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr.

  32. Slide 32: Management Team – Himanshu Patel

    32 Management team Himanshu Patel – Chief Technology Officer Himanshu Patel has served as Chief Technology Officer of Avinger since its founding in 2007. Mr. Patel brings over 25 years of design experience developing medical devices, primarily for cardiovascular and peripheral artery disease treatme

  33. Slide 33: Patent Overview

    Patent overview As of December 31, 2017 42 U.S. patents and patent applications 17 allowed & issued US patents 25 pending utility applications 73 Ex-U.S. patents and patent applications 26 allowed & issued ex-US patents 41 Pending nationalized ex-US applications 6 pending PCT applications 115 Total

  34. Slide 34: Patent Overview

    AS OF DECEMBER 31, 2017 {0} PATENT OVERVIEW +» Avinger has an extensive IP portfolio covering key aspects of the design, manufacturing and therapeutic use of OCT imaging catheters, atherectomy devices and imaging console 42 U.S. patents and patent applications - 17 allowed & issued US patents — 25 p

  35. Slide 35: Accurately Size BTK Vessels

    Min Diameter = 4.2mm Max Diameter = 4.4mm Lumen Area = 14.4mm2 Min Diameter = 4.8mm Max Diameter = 5.0mm Lumen Area = 18.5mm2 PROXIMAL OVERLAP – TIGHTEST STENOSIS PROXIMAL OVERLAP – TIGHTEST STENOSIS OUTER STENT INNER STENT 35 Min Diameter = 4.2mm Max Diameter = 4.4mm Lumen Area = 16.mm2 ACCURATELY

  36. Slide 36: VISION IDE Pantheris Clinical Data

    36 VISIO N IDE PA N T H ER I S CL I N I CA L DA T A P AN T H E R I S 201 7 P AG E 21

  37. Slide 37: Chronic Total Occlusion

    CHRONIC TOTAL OCCLUSION 20% of Total Cohort Treated (N=33) Identical TLR rate of non-CTO cohort

  38. Slide 38: Freedom from TLR by Lesion

    24 MONTH OUTCOMES FREEDOM FROM TLR BY LESION Months since directional atherectomy with Pantheris catheter Freedom from TLR (%) 76% @ 24 months 83% @ 12 months 77% @ 18 months 38

  39. Slide 39: Freedom from TLR by Patient

    24 MONTH OUTCOMES FREEDOM FROM TLR BY PATIENT Months since directional atherectomy with Pantheris catheter 39 74% @ 24 months 75% @ 18 months 82% @ 12 months

  40. Slide 40: CONNECT II Ocelot Clinical Data

    40 Connect ii Ocelot clinical data Avinger’s CONNECT II is an FDA approved prospective, non-randomized, global clinical study that evaluated the safety and efficacy of the Ocelot System.

  41. Slide 41: References

    (1) Roguin et. al. AJC. May 2013. Vol.111(9): 1368-1372 (2) Vano et. al. Radiation Research. 2010.174(4): 490-495 (3) Ruso G. et. al. European Heart Journal. 2001 (4) Shope TB Radiographics. 1996. 16(5): 1195-9 (5) Segal E. et. al. JVS. 2013.58(6): 1556-62 AVINGER OVERVIEW 2017 PAGE 41

  42. Slide 42: References

    Staniloae, Cezar S., et al. "Endoluminal treatment of peripheral chronic total occlusions using the Crosser® recanalization catheter." Journal of Invasive Cardiology 23.9 (2011): 359 Laird, John R., et al. "Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent gra

  43. Slide 43: Zero Contrast and Reduced Radiation for CKD

    Zero Contrast and Reduced Radiation For CKD (1) J. Invasive Cardiol. 2014 Aug; 26(8):363-9 43

  44. Slide 44: Zero Contrast and Reduced Radiation for CKD

    (3) ZERO CONTRAST AND REDUCED RADIATION FOR CKD Lumivascular 280mm SFA CTO 1} Constrast = OmL 2) Total Radiation = 0.3 Gy 2) DAP = 56.5 Gy-cm2 Endovascular’ Average 140mm SFA CTO 1) Constrast = 187.8 +/- 72mL 2) Radiation = 39.1 +/- 21.2 min 2) DAP = 210 +/- 212 Gy-cm2 @avinoer 300 228 187.0 56.5 0.

  45. Slide 45: Wildcat CTO Crossing Catheter

    i j LvoalmM © ‘The perfect balance of brains and brawn, Wildcat’s robust feel and 6 different modes make it the essential tool for crossing CTOs. EFFECTIVE INCROSSING CTOs —_JUICEBOX COMPATIBLE 89.3% crossing success rate, 95.2% safety rate, ‘Simpliies the procedure by providing powered tip rotation

  46. Slide 46: Technical Specifications

    TECHNICAL SPECIFICATIONS. j g i ZIVOALLIN©- {ts shapeable tip and 150cm in tength allows KC2 to go further. ‘SMALL PROFILE Maneuverable through small vessels with SF sheath. ‘SPIRAL FLUTES: Exposed spiral flutes with a gentler approach for lesion access. EXTRA, EXTRA LENGTH 150cm length offers exten

Avinger — IPO Roadshow (February 2018) on 6ix